Schizophrenia and the gut–brain axis

@article{Nemani2015SchizophreniaAT,
  title={Schizophrenia and the gut–brain axis},
  author={K. Nemani and R. H. Ghomi and B. Mccormick and Xiaoduo Fan},
  journal={Progress in Neuro-Psychopharmacology and Biological Psychiatry},
  year={2015},
  volume={56},
  pages={155-160}
}
Several risk factors for the development of schizophrenia can be linked through a common pathway in the intestinal tract. It is now increasingly recognized that bidirectional communication exists between the brain and the gut that uses neural, hormonal, and immunological routes. An increased incidence of gastrointestinal (GI) barrier dysfunction, food antigen sensitivity, inflammation, and the metabolic syndrome is seen in schizophrenia. These findings may be influenced by the composition of… Expand
The brain-gut axis dysfunctions and hypersensitivity to food antigens in the etiopathogenesis of schizophrenia.
TLDR
Research results seem to be very promising and indicate the possibility of improved clinical outcomes in some patients with schizophrenia by modifying diet, use of probiotics, and the implementation of antibiotic therapy of specific treatment groups, however, further research is needed on links between the intestinal microbiome and intestinal function as factors mediating the activation of the immune system. Expand
Chapter 16 – The Influence of Diet and the Gut Microbiota in Schizophrenia
TLDR
The goal of this chapter is to describe the current literature as it pertains to one particular aspect of schizophrenia—the complex interplay between the gut and the brain. Expand
The gut microbiota in neuropsychiatric disorders.
TLDR
Current knowledge about the gut microbiota in neuropsychiatric disorders suggests that specific bacteria can be involved in the development of clinical conditions, such as Autism Spectrum Disorders, depression and schizophrenia, and microbiota may be a target for therapeutic intervention providing novel treatment strategies. Expand
Gut microbiota: An intermediary between metabolic syndrome and cognitive deficits in schizophrenia
TLDR
An important role of the microbiome in the metabolism of schizophrenia and the potential for AAPDs to change the gut microbiota to promote adverse events are focused on. Expand
The role of microbiota in the pathogenesis of schizophrenia and major depressive disorder and the possibility of targeting microbiota as a treatment option
TLDR
Despite the accumulated knowledge in this field, more studies are warranted and required to further the understanding of the brain-gut axis and the possibility of targeting microbiota as a treatment option for schizophrenia and major depressive disorder. Expand
Gut-brain axis: A matter of concern in neuropsychiatric disorders…!
The gut microbiota is composed of a large number of microbes, usually regarded as commensal bacteria. It has become gradually clear that gastrointestinal microbiota affects gut pathophysiology andExpand
Gut–Brain Axis: A New Revolution to Understand the Pathogenesis of Autism and Other Severe Neurological Diseases
TLDR
The gut microbiota can modulate brain function, forming a crucial link in the bidirectional interactions between the intestine and the nervous system. Expand
Interactions between the gut microbiome and the central nervous system and their role in schizophrenia, bipolar disorder and depression
TLDR
The aim of this review is to summarize the recognized pathways of the gut–brain axis that have been thoroughly studied in animal models and to evaluate the role of the dialogue between the microbiota and the central nervous system in schizophrenia, bipolar disorder and depression. Expand
The interplay between gut microbiota and autism spectrum disorders: A focus on immunological pathways
TLDR
An overview of how gut microbes and their metabolites are associated with neurobehavioral features of ASD through various immunologic mechanisms is provided and the potential therapeutic options that could modify these features are discussed. Expand
The Gut-Brain Axis, BDNF, NMDA and CNS Disorders
TLDR
This review focuses on the influence of the GI tract on Brain-Derived Neurotrophic Factor (BDNF) and its relationship with receptors for N-methyl-d-aspartate (NMDAR), as these are believed to be involved in synaptic plasticity and cognitive function. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 101 REFERENCES
The metabolic syndrome in schizophrenia: is inflammation a contributing cause?
TLDR
It is concluded that the effects of inflammatory mediators on the brain causally contribute to the pathology of schizophrenia and the ill health that accompanies the disorder. Expand
Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour
TLDR
The emerging concept of a microbiota–gut–brain axis suggests that modulation of the gut microbiota may be a tractable strategy for developing novel therapeutics for complex CNS disorders. Expand
The new link between gut–brain axis and neuropsychiatric disorders
TLDR
This review summarizes some recent findings that may localize the origin of eating disorders as well as some other neuropsychiatric disorders outside the brain and discuss their cause as a possible dysfunction of the gut–brain axis involving the humoral immune system. Expand
The microbiome‐gut‐brain axis: from bowel to behavior
  • J. Cryan, S. O'Mahony
  • Biology, Medicine
  • Neurogastroenterology and motility : the official journal of the European Gastrointestinal Motility Society
  • 2011
TLDR
It is shown that germ‐free mice display alterations in stress‐responsivity, central neurochemistry and behavior indicative of a reduction in anxiety in comparison to conventional mice, offering the enticing proposition that specific modulation of the enteric microbiota may be a useful strategy for stress‐related disorders and for modulating the co‐morbid aspects of gastrointestinal disorders such as irritable bowel syndrome and inflammatory bowel disease. Expand
Effect of intestinal microbial ecology on the developing brain.
TLDR
A brief review of the intestinal microbiome is provided, with a focus on new studies showing that there is an important link between the microbes that inhabit the intestinal tract and the developing brain. Expand
Gastrointestinal inflammation and associated immune activation in schizophrenia
TLDR
Gastrointestinal inflammation is a relevant pathology in schizophrenia, appears to occur in the absence of but may be modified by antipsychotics, and may link food antigen sensitivity and microbial infection as sources of immune activation in mental illness. Expand
Inflammation and schizophrenia
TLDR
Inflammation might be an important common pathophysiological process related to both schizophrenia psychopathology and metabolic disturbances seen in patients with schizophrenia, and future studies targeting proinflammatory cytokines and their molecular signaling pathways may lead to novel pharmacological intervention strategies treating both psychopathological and medical comorbidity in patientswith this devastating mental illness. Expand
Autoimmune diseases and infections as risk factors for schizophrenia
TLDR
Autoimmune diseases and infections should be considered in the treatment of individuals with schizophrenia symptoms, and further research is needed of the immune system's possible contributing pathogenic factors in the etiology of schizophrenia. Expand
The role of microbes and autoimmunity in the pathogenesis of neuropsychiatric illness
  • M. Hornig
  • Medicine
  • Current opinion in rheumatology
  • 2013
TLDR
An increased prevalence of familial autoimmunity, exposure to pathogens prenatally and postnatally, and findings of antibrain antibodies is common in disorders as diverse as schizophrenia, obsessive-compulsive disorder and autism, and suggests that differences in exposure timing and genetic vulnerability toward autoimmonity are important determinants of neuropsychiatric outcomes. Expand
Antipsychotics and the gut microbiome: olanzapine-induced metabolic dysfunction is attenuated by antibiotic administration in the rat
TLDR
The results suggest that the gut microbiome has a role in the cycle of metabolic dysfunction associated with olanzapine, and could represent a novel therapeutic target for preventing antipsychotic-induced metabolic disease. Expand
...
1
2
3
4
5
...